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Abstract The phosphatidylinositol 3-kinase (PI3K)/AKT
pathway is frequently upregulated in human cancer. Activa-
tion of this pathway has been reported to be associated with
resistancetovarious chemotherapeuticalagents.We hereused
a chemical biology/chemical informatic approach to identify
apoptotic mechanisms that are insensitive to activation of the
PI3K/AKT pathway. The National Cancer Institute (NCI)
Mechanistic Set drug library was screened for agents that
induce apoptosis in colon carcinoma cells expressing a
constitutively active form of AKT1. The cytotoxicity screen-
ing data available as self-organized maps at the Developmen-
tal Therapeutics Program (DTP) of the NCI was then used to
classify the identified compounds according to mechanism of
action. The results showed that drugs that interfere with the
mitotic process induce apoptosis which is comparatively
insensitive to constitutive AKT1 activity. The conditional
screening approach described here is expected to be useful for
identifying relationships between the state of activation of
signaling pathways and sensitivity to anticancer agents.
Keywords Chemicalbiology.Apoptosis.AKT.
Microtubuli-interactingagents
Introduction
The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is
frequently upregulated or activated in human cancer. The class
I subgroup of PI3Ks is thought to exclusively phosphorylate
PtdIns(4,5)P2 to generate PtdIns(3,4,5)P3 (PIP3) in vivo [41].
PIP3 induces the membrane localization and activation of the
proto-oncogenic kinase AKT/protein kinase B (PKB) [39].
While AKT mutations are less common, PI3K is often
amplified in cancer [39]. Oncogenic signaling via activated
tyrosine kinase receptors and mutated Ras will also lead to
high constitutive activation of PI3K and hence also of AKT
[14,34]. Furthermore, the counteractive tumor suppressor
PIP3 phosphatase PTEN (phosphatase and tensin homolog
deleted on chromosome 10) is frequently mutationally
inactivated in many types of cancer [26]. Downstream effector
pathways of AKT include the anti-apoptotic protein Bad,
inhibition of Mdm2, p27Kip, and activation of mammalian
target of rapamycin, mTOR [11]. mTOR regulates both cell
growth and cell cycle progression through its ability to
integrate signals from nutrient and growth factor stimuli.
Inadditiontocontributingtotumorigenesis,thePI3K/AKT
pathway is strongly implicated in chemoresistance. A number
of investigators have reported that AKT is a key factor in
conferring cellular resistance to various chemotherapeutical
agents in vitro, including cisplatin, oxaliplatin, and etoposide
[1,2,4,6,8,23,25,29,36]. Furthermore, AKT promotes cell
survival after exposure to such different death stimuli as
UV irradiation, growth factor withdrawal, TGF-ß, anti-Fas
antibody, glutamate, and bile acids [9,10,12,16,21,22].
Cellular responses to anticancer drugs are complex and
may include apoptosis, necrosis, premature senescence, and
mitotic catastrophe [7,35]. In order to examine the role of
AKT specifically in apoptosis induced by chemotherapeutic
drugs and to identify drugs which induce apoptosis
independently of AKT1 activity, we have here screened a
chemical library on an isogenic pair of HCT116 cell lines,
one of which expresses wild-type AKT1 which by myristy-
lation is made constitutively membrane-bound and active.
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Materials
The mechanistic set was obtained from the Developmental
Therapeutics Program of the US National Cancer Institute
(http://www.dtp.nci.nih.gov). AKT antibody was from Cell
Signaling (Beverly, MA), β-tubulin antibody from Sigma–
Aldrich (St Louis, MO), and antibody to phosphorylated
GSK3β was a gift from Katja Pokrovskaja (Cancer Center,
Karolinska).
Cell culture
HCT116 colon carcinoma cells stably expressing constitutive-
ly active myristoylated AKT (myr-AKT), and parental cells
were generously provided by Dr Nissim Hay (University of
IllinoisatChicago,IL).Cellsweremaintained in McCoy’s5 A
modifiedmediumsupplementedwith10% fetal calf serum,L-
glutamate, penicillin, and streptomycin (and 10 μg/ml
puromycin for AKT-transfected cells) at 37 in 5% CO2. Cell
survival was examined using the sulphorhodamine (SRB)
assay as described [17].
Screening and assessment of apoptosis
HCT116 cells were seeded in 96-well microtiter plates at
10,000 cells per well in 200 μl medium and incubated
overnight. Drugs were then added to a final concentration
of 2.5 or 5 μM from stocks in DMSO (to a final
concentration of 0.5%). Control wells received vehicle
only. After 24 h of incubation, NP-40 was added directly to
the tissue culture medium to a final concentration of 0.1%
followed by mixing on a rotatory shaker for 5 min. A 25-μl
aliquot of the content of each well was assayed for caspase-
cleaved CK18 using the M30-CytoDeath® ELISA assay (a
modification of the M30-Apoptosense® ELISA intended
for in vitro use; PEVIVA AB, Bromma, Sweden) [19].
Formation of the cleaved product depends on caspase
activity and is inhibited by pan-caspase inhibitors such as
zVAD-fmk.
siRNA transfection
Cells were seeded in the presence of transfection reagents
(25 nM siRNA, HiPerfect Transfection reagent; Dharma-
con) and incubated for 48 h. Cells were then either drug
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Fig. 1 Phenotype of HCT116-myr-AKT cells. a AKT expression in
HCT116 and HCT116-myr-AKT cells. Cell extracts were analyzed for
AKT expression by western blotting using an antibody to human AKT.
Cells were transfected with AKT siRNA where indicated; b increased
phosphorylation of AKT at T473 in HCT116-myr-AKT cells. AKT
phosphorylation was examined by western blotting using an antibody to
the phosphorylated form of the protein. The same blot was probed with
an antibody to total AKT. c Increased phosphorylation of GSK3β in
HCT116-myr-AKT cells. GSK3β phosphorylation was examined by
western blotting using an antibody to the phosphorylated form of the
protein. The same blot was probed with an antibody to β-tubulin.
d Increased sensitivity of HCT116-myr-AKT cells to 2-deoxyglucose.
Cells were treated with the indicated concentrations of 2-deoxyglucose
and survival was examined using the SRB assay; *p<0.05; **p<0.005.
e Apoptosis induction by cisplatin and camptothecin in HCT116-myr-
AKT cells. Cells were treated for 24 h, and apoptosis was quantified
using the M30 CytoDeath® ELISA. f Effect of AKT siRNA on
apoptosis induced by one of the agents in the set (NSC NSC632841).
Cells were transfected with siRNA as indicated and treated with the
drug for 24 h. Caspase-cleaved CK18 was determined using the M30
CytoDeath® ELISA
82 J Chem Biol (2009) 2:81–87treated for apoptosis assessment or lysed for Western
blotting. Cell extract proteins were resolved by NuPage
Bis-Tris gels (Invitrogen) and transferred onto a polyviny-
lidene difluoride membrane. Membranes were probed with
antibodies to AKT (dilution 1: 2,000), AKT T473 (dilution
1:1,000), or β-tubulin (dilution 1:1,000).
SOM clustering
The web-based tool available at http://spheroid.ncifcrf.gov/
spheroid/HTMLNscNumberProjection.cfm w a su s e dt om a p
the apoptotic compounds onto the self organizing maps
(SOMs). This tool has been developed by the Covell group at
the National Cancer Institute at Frederick and utilizes
biological data (tumor cell growth inhibition (GI50)) to
generate SOMs [32]. The SOMs represent a neural network-
based algorithm [24] able to project high-dimensional data
into lower dimensional space. For compounds that generated
more than one map position, the strongest association was
used.
Results and discussion
Characterization of an HCT116 cell line expressing
myristylated AKT/PKB We here used an HCT116 colon
carcinoma cell line engineered to express a myristylated form
of AKT that is constitutively membrane-bound and active
(HCT116-myr-AKT, generously provided by Dr. Nissim
Hay). Western blot analysis confirmed higher levels of AKT
in HCT116-myr-AKT cells relative to parental cells (Fig. 1a)
and increased phosphorylation of AKT at S473 (Fig. 1b).
Furthermore, increased phosphorylation of the AKT target
GSK3β was observed in HCT116-myr-AKT cells (Fig. 1c).
In accordance with a requirement for glycolysis in the
survival functions of AKT [13], HCT116-myr-AKT cells
showed an increased sensitivity to the glycolysis inhibitor 2-
deoxyglucose (1–20 mM), as assessed in a survival assay
over 48 h (Fig. 1d). Furthermore, HCT116-myr-AKT cells
were less sensitive to apoptosis induced by cisplatin and
camptothecin (Fig. 1e).
In order to confirm the role of myr-AKT expression for
the apoptotic response, we transfected HCT116-myr-AKT
and control cells with AKT siRNA. The transfection
resulted in significantly decreased AKT expression in both
cell lines (Fig. 1a). Transfected cells were then treated with
one of the apoptotic compounds from the NCI Mechanistic
Set (4-piperidinone, 1-(1-oxo-2-propenyl)-3,5-bis(phenyl-
methylene)), As shown in Fig. 1f, untransfected control and
myr-AKT cells showed different responses to NSC632841,
whereas the apoptotic response was similar in both cell
lines when transfected with AKT siRNA. We conclude
from these experiments that HCT116-myr-AKT cells show
the expected phenotype with regard to signaling and drug
sensitivity.
Screening for compounds that induce myr-AKT-insensitive
apoptosis In order to identify agents that are effective in
inducing apoptosis of HCT116-myr-AKT cells, we exposed
the pair of cell lines to the NCI Mechanistic drug set at 2.5 or
5 µM. This drug collection contains 827 compounds selected
from approximately 40,000 compounds on the basis on
d i f f e r e n tm e c h a n i s m so fa c t i o nw i t hr e g a r dt oc e l lg r o w t h
inhibition of the NCI60 tumor cell line panel. We initially
screened the entire drug set for compounds effective in
inducing apoptosis of HCT116 then used a selection of
apoptosis-inducing compounds on the cell pair. Apoptosis
was measured by the M30 CytoDeath® ELISA, an assay
whichisspecificfor a caspase-cleavedproduct ofcytokeratin-
18 formed in apoptotic cells [19]. The apoptosis product
accumulates in cell cultures and was measured at a single
time point (24 h). The signals from untreated myr-AKT and
control cells were set to 1, respectively. For each drug, the
induced levels of apoptosis in each cell line were then plotted
against each other (Fig. 2). Drugs that induced less than
twofold the background apoptosis in parental cells are
excluded from the figure. Most of the drugs shown generated
a sufficient signal at a concentration of 2.5 µM. It is clear
HCT116 (FOLD CK18-Asp396)
 
H
C
T
1
1
6
 
m
y
r
-
A
k
t
 
(
F
O
L
D
 
C
K
1
8
-
A
s
p
3
9
6
)
 
0
4
8
8
10
6
2
246 1 0
y = 0.70x
y = x
Fig. 2 Apoptotic responses of myr-AKT and control HCT1116 cells
treated with 2.5 µM of NCI Mechanistic Set agents. With a minority
of agents, 5 µM was required. Caspase-cleaved CK18 was measured
in extracts and medium after 24 h of treatment using the M30
CytoDeath® ELISA. Only agents inducing caspase-cleaved CK18 of
greater than twofold control are included in the figure. The best-fit line
of the dataset is shown
J Chem Biol (2009) 2:81–87 83from the result (Fig. 2) that most compounds induced
stronger apoptotic responses in control cells compared to
myr-AKT cells (the slope of the best-fit curve is 0.70).
However, and importantly, a number of compounds induced
similar levels of apoptosis regardless of cellular AKT status.
Drugs whose ratios of apoptosis induction in HCT116-
myr-AKT to control HCT116 cells were ≥0.9 were classified
as AKT-insensitive. There were 17 such drugs (Table 1).
Fifteen compounds were found to induce an apoptotic
response in HCT116-myr-AKT cells that was <50% of
control cells and were classified as AKT-sensitive (Table 2).
Characteristics of compounds inducing similar levels of
apoptosis in myr-AKT and control HCT116 cells Based on
responses in the NCI60 cancer cell line panel, the profiles
of cell growth inhibition of the drugs tested by the NCI
Developmental Therapeutics Program have been assembled
into SOMs, where the position of a particular drug reflects
its main target process or mechanism of action [32]. Most
of the agents currently in clinical use map to the M and
S areas of these maps (M = mitosis, S = nucleic acid
synthesis; Fig. 3a). We used a web-based tool to determine
where the apoptotic compounds map on these SOMs (see
“Material and methods”). Approximately half (34/62) of the
compounds identified by screening as inducing apoptosis in
HCT116 cells (shown in Fig. 2) mapped in the M and S
areas and 15 mapped to the Q region which is associated
with metabolic stress.
AKT-sensitive and AKT-insensitive compounds showed
different distributions on the maps (Fig. 3c, d). AKT-sensitive
drugs mapped in the S region (6/15), in the Q region (6/15),
but not in the M region (0/15). In contrast, 11/17 AKT-
insensitive drugs mapped in the M-region and only 2/17 in
the S region. The difference in distribution of AKT-sensitive
and AKT-insensitive drugs to the M area was statistically
highly significant (Fisher exact test: p=0.00011).
As expected, the group of AKT-insensitive drugs mapping
to the M region included typical microtubuli-targeting drugs
such as colchicine, vinblastine, and podophyllotoxin. In
addition, drugs such as actinomycin-D, tetrocarcin, and
thaspine were found in this group. Whereas actinomycin-D
has been observed to inhibit tubulin polymerization in vitro
[33], such activities have not been reported for tetrocarcin A
or thaspine. Tetrocarcin A has been reported to inhibit Bcl-2
function [28], while the mechanism of thaspine cytotoxicity
is not well characterized.
NSC number Name SOM Region(s) Cancer active
a
757 Colchicine M Leukemia
Carcinoma
Sarcoma
18268 Dactinomycin M Leukemia
Carcinoma
24819 Peltatin M Leukemia
Carcinoma
24818 Podophyllotoxin M Leukemia
Sarcoma
33410 Colchicine, N- M Leukemia
Benzoyl-deacetyl Melanoma
49842 Vinblastine M Leukemia
Carcinoma
76022 Thaspine M Sarcoma
83265 Tritylcysteine N Leukemia
Carcinoma
85236 Helenalin Q Leukemia
219734 M Leukemia
Carcinoma
333856 Tetrocarcin M Melanoma
345647 Chaetochromin M Carcinoma
639828 M nt
647889 P nt
651079 S nt
687850 Q nt
705701 Alsterpaullone S nt
Table 1 myr-AKT-insensitive
drugs
Drugs inducing similar levels of
apoptosis in parental and
myr-AKT expressing HCT116
cells
aDrugs that induce increased
survival and/or decreases in
tumor mass according to testing
performed at the National
Cancer Institute (http://www.
dtp.nih.nci.gov) were classified
as cancer active
nt not tested
84 J Chem Biol (2009) 2:81–87Of the 17 AKT-insensitive drugs, 12 have been tested for
anti-tumor activity by the Developmental Therapeutics
Program (http://dtp.nci.nih.gov). All 12 were found to have
antitumor activity in animal models (Table 1). Three of the
active compounds are well-known cytostatics, podophyllo-
toxin, vinblastine, and actinomycin-D. Of the remaining,
NSC219734 is a DNA intercalating diacridine [15].
NSC526417 is dithiocarbamate, an agent found to have
activity on leukemias and carcinomas. Finally, thaspine
(NSC76022) is an alkaloid present in the cortex of the tree
Croton lechleri which grows in the upper Amazon region of
Peru, Ecuador, and Colombia. A red latex, Dragon’sb l o o d
(Sangre de drago), is extracted from the cortex of the tree
and is extensively used by different tribes of the Amazonian
basin for medicinal purposes. Thaspine was previously
reported to be cytotoxic [20,40] and to have antitumor
activity [40] and may be an interesting anticancer drug.
Helenalin (NSC85236) is often used in vitro as an NFκB
inhibitor, but apoptosis induction by helenalin in the myr-
AKT cells is in line with its reported inhibitory effect on
AKT [3] and its SOM location in the Q region. We have
reported that helenalin induces apoptosis via CaMKII,
ASK1, and JNK [30].
Based on the present apoptosis screening and further
analysis using SOMs, we conclude that expression of
constitutively active AKT mainly affected apoptosis induced
byDNA-damagingdrugs,whereasAKT-insensitiveapoptosis
was associated mainly with drugs that interfere with the
process of mitosis. This conclusion is supported by the report
that expression of constitutively active AKT1 in A549 human
non-small cell lung carcinoma cells resulted in increased
survival in response to mitoxantrone and cisplatin but not to
microtubuli-interacting agents such as paclitaxel [36]. That
apoptosis induced by mitotic inhibitors is insensitive to AKT
overexpression is not altogether unexpected since apoptosis
induced by mitotic inhibitors is likely to be secondary to
mitotic catastrophe and not a primary signaling event [27]. In
contrast to these results, other authors have reported that
myr-AKTconfers resistance to microtubuli-interacting agents
[38]. We suggest that this different result is due to the use of
non-transformed IL-3 dependent hematopoietic cells rather
than transformed epithelial cells. These cell types likely
differ in signaling pathways that regulate survival energy
metabolism and microtubule functions. Furthermore, due to
Table 2 myr-AKT-sensitive drugs
NSC number Name SOM region(s)
285116 Siomycin P
72961 8-Adenosine V
47147 Prodigiosin S
152731 S
123111 Mitomycin derivative S
162907 Ellipticine, 6-(5-hexen-1-yl-) R
335142 S
651084 Q
687849 Q
638645 Q
636676 Q
173904 Carbamic acid, ester Q
629971 9-Amino-20-camptothecin S
697923 Q
146604 5-Fluorouridine S
Drugs that induced more apoptosis in parental than in myr-AKT
expressing HCT116 (ratio>2)
APOPTOTIC SET AKT INSENSITIVE SET AKT SENSITIVE SET CONVENTIONAL AGENTS AB C D
Fig. 3 Exploration of mechanisms of action of different sets of drugs
using self-organizing maps (3D Mind resource; http://spheroid.ncifcrf.
gov/spheroid). SOM clustering of the NCI60 GI50 data segregates
compounds into nine major response categories: mitosis (M); nucleic
acid metabolism (S); metabolic stress and cell survival (Q); membrane
function (N); kinases/phosphatases and oxidative stress (P); and four
unexplored regions, R, F, J, and V [18]. a Examples of drugs are in
clinical use (mostly mapping in the M and S areas); b Mapping of 62
drugs in the NCI mechanistic set which induce strong apoptosis of
HCT116 cells; c mapping of AKT-sensitive drugs (note the preferen-
tial location to the S and Q regions); d Mapping of AKT-insensitive
drugs (note the preferential location to the M region)
J Chem Biol (2009) 2:81–87 85the documented roles of AKT in anti-apoptotic pathways
[31], we have focused exclusively on acute apoptosis,
whereas the other report is based on survival seen as levels
of propidium iodide exclusion after 72-h treatment [38].
Over this time interval, microtubuli-interacting agents are
expected to induce mitotic arrest followed by secondary
apoptosis, and it is possible that this cell death is sensitive to
blocking by constitutively active AKT.
Cell-based assays have the advantage of reasonable
experimental through-put while preserving disease-relevant
molecular-pathway interactions [5]. This is particularly
important in the field of oncology due to the complex
mechanisms of action of cytotoxic drugs [37]. The condi-
tional cell-based phenotypic screening approach used here
promises be effective in defining drug mechanisms that are
insensitive to overexpression of various oncogenes, loss of
tumor suppressors, or other phenotypic traits. Such studies
are important in order to define the proper use of cancer
drugs in clinical oncology.
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